Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Ozcan, Muhit
[Clear All Filters]
2023
Atesoglu EBirtas
,
Gulbas Z
,
Uzay A
,
Ozcan M
,
Özkalemkaş F
,
Dal MSinan
,
Kalyon H
,
Akay OMeltem
,
Deveci B
,
Bekoz H
, et al.
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Hematol Oncol. 2023.
PubMed
Google Scholar
Zinzani PLuigi Luig
,
Thieblemont C
,
Melnichenko V
,
Bouabdallah K
,
Walewski J
,
Majlis A
,
Fogliatto LMaria
,
Garcia-Sancho AMartin
,
Christian B
,
Gulbas Z
, et al.
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.
Blood. 2023.
PubMed
Google Scholar
2021
Kuruvilla J
,
Ramchandren R
,
Santoro A
,
Paszkiewicz-Kozik E
,
Gasiorowski R
,
Johnson NA
,
Fogliatto LMaria
,
Goncalves I
,
de Oliveira JSR
,
Buccheri V
, et al.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Lancet Oncol. 2021.
PubMed
Google Scholar
Zinzani PLuigi
,
Ramchandren R
,
Santoro A
,
Paszkiewicz-Kozik E
,
Gasiorowski R
,
Johnson NA
,
Oliveira JSR
,
Buccheri V
,
Perini GFleury
,
Dickinson M
, et al.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Blood Adv. 2021.
PubMed
Google Scholar
2020
Atilla PAtaca
,
Akkus E
,
Atilla E
,
Gokmen N
,
Bozdağ SCivriz
,
Toprak SKocak
,
Yuksel MKurt
,
Ozcan M
,
Demirer T
,
Ilhan O
, et al.
Effects of ABO incompatibility in Allogeneic Hematopoietic Stem Cell Transplantation.
Transfus Clin Biol. 2020.
PubMed
Google Scholar
2018
Atilla E
,
Yalciner M
,
Atilla PAtaca
,
Ates C
,
Bozdağ SCivriz
,
Yuksel MKurt
,
Toprak SKocak
,
Gunduz M
,
Ozen M
,
Akan H
, et al.
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?
. Antivir Ther. 2018.
PubMed
Google Scholar
2016
Atilla E
,
Topcuoglu P
,
Ataca P
,
Pekcan G
,
Bozdag SCivriz
,
Yuksel MKurt
,
Ozcan M
,
Gürman G
,
Toprak SKocak
.
A rare complication after allogeneic stem cell transplantation: post-transplant erythrocytosis.
Clin Transplant. 2016.
PubMed
Google Scholar